Novartis (NYSE: NVS) reported Q2 EPS of $1.83, $0.12 better than the analyst estimate of $1.71. Revenue for the quarter came in at $13.62 billion versus the consensus estimate of $13.51 billion.

Full-year 2023 Group guidance raised based on strong H1 momentum. Group sales expected to grow high single digit (from mid). Group core operating income expected to grow low double digit (from high single).

For earnings history and earnings-related data on Novartis (NVS) click here.